Pharmaceutical Quality by Design Development[通过设计与开发药物质量](PPT-66).ppt

Pharmaceutical Quality by Design Development[通过设计与开发药物质量](PPT-66).ppt

  1. 1、本文档共66页,可阅读全部内容。
  2. 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
PharmaceuticalQualitybyDesign

2006.08.22. Pogány - Dar es Salaam */66 Manufacturing Process Development An assessment of the ability of the process to reliably produce a product of the intended quality e.g., the performance of the manufacturing process under different operating conditions, at different scales, or with different equipment can be provided. Unsatisfactory processes must be modified and improved until a validation exercise proves them to be satisfactory. An understanding of process robustness can be useful in risk assessment and risk reduction. 2006.08.22. Pogány - Dar es Salaam */66 The remaining steps Pharmaceutical equivalence and bioequivalence with innovator product has been demonstrated Production batches validated Compilation of the dossier for prequalification Prequalification procedure GMP inspection Listing the FPP on the PQ website 2006.08.22. Pogány - Dar es Salaam */66 Main points again Development pharmaceutics is an essential part of applications for prequalification. Desk research gives valuable design and development information. The specifications of an API are finalized during pharmaceutical development studies. FPP design, characterization and selection should follow a scientific methodology. Manufacturing process design and optimization identifies the critical attributes whose control leads to the batch-to-batch consistency of quality. 2006.08.22. Pogány - Dar es Salaam */66 THANK YOU * * * * * FOURTH INVITATION FOR EXPRESSION OF INTEREST (EOI) (Artemisinin based Antimalarial Products) May 2005 In the context of facilitating access to Artemisinin based combination antimalarial drug products, Roll Back Malaria (RBM) Department of the World Health Organization, UNICEF and UNDP are inviting Expressions of Interest from manufacturers of pharmaceutical products in respect to the provision of drugs for the management of malaria. The World Bank is in support of this effort. This fourth invitation is published in order to increase the range of possible product

文档评论(0)

bodkd + 关注
实名认证
内容提供者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档